Mirtazapine

George Papakostas

A. General information

· Contraindicated in patients on MAOI inhibitors.

B. B. Metabolism and phamacokinetics

· Hepatically metabolized.

· Elimination: 85% renal, 15% fecal.

· Need to adjust for both GFR and hepatic impairment

C. Side Effects.

· CNS: Somnolence, Dizziness

· Hematologic: agranulocytosis, incidence 1.1/1000 patients

· Endocrinologic: Wt. gain, hyperlipidemia, hypercholesteremia.

· Gastrointestinal: Transient elevation of LFT’s;

Nausea, dry mouth.

· CV: palpitations, hypotension.